The clinical activity of rituximab, a chimeric monoclonal antibody which binds to the CD20
antigen, was evaluated as a single first-line therapy for patients with follicular non-Hodgkin
lymphoma (NHL). Fifty patients with follicular CD20+ NHL and a low tumor burden were
analyzed for clinical and molecular responses. They received 4 weekly infusions of
rituximab at a dose of 375 mg/m2. The response rate a month after treatment (day 50) was
36 of 49 (73%), with 10 patients in complete remission, 3 patients in complete …

Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with
follicular lymphoma with a low tumor burden : Clinical and molecular evaluation | CiNii
Research … Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for
patients with follicular lymphoma with a low tumor burden : Clinical and molecular evaluation …